Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Journal:

The New England Journal of Medicine

Published:

2025-10-20

DOI:

10.1056/nejmoa2510310

Affiliations:

25

Authors:

20

Go to article

Institutions	Authors	Share
Pfizer, United States of America (USA)	3.000000	0.15
Astellas US LLC, United States of America (USA)	2.000000	0.10
Ewha Woman’s University Mokdong Hospital, South Korea	1.000000	0.05
Instituto Valenciano de Oncologia (IVO), Spain	1.000000	0.05
Chesapeake Urology, United States of America (USA)	1.000000	0.05
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy	1.000000	0.05
Hospital Erasto Gaertner, Brazil	1.000000	0.05
South Texas Accelerated Research Therapeutics, LLC (START), United States of America (USA)	1.000000	0.05
Vancouver Prostate Centre (VPC), Canada	1.000000	0.05
Associated Medical Professionals, United States of America (USA)	1.000000	0.05
Calvary Mater Newcastle, Australia	1.000000	0.05
University of Glasgow, United Kingdom (UK)	0.666667	0.03
HUS Helsinki University Hospital, Finland	0.500000	0.03
Southern Alberta Institute of Urology (SAIU), Canada	0.500000	0.03
University of Calgary (U of C), Canada	0.500000	0.03
Blacktown and Mount Druitt Hospital (BMDH), Australia	0.500000	0.03
Hôpital Claude Huriez, France	0.500000	0.03
University of Lille (UDL), France	0.500000	0.03
University of Helsinki, Finland	0.500000	0.03
Chris O'Brien Lifehouse, Australia	0.500000	0.03
Durham VA Medical Center (VAMC), United States of America (USA)	0.500000	0.03
Cedars-Sinai Medical Center (Cedars-Sinai), United States of America (USA)	0.500000	0.03
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	0.333333	0.02

Interested in Oncology and Carcinogenesis?